youtube_live
Q3 2026 earnings • released • EPS beat +11.13%
See resultschevron_right
PRAX:NASDAQ
Praxis Precision Medicines Inc
$332.97
arrow_upward
+19.94%(+55.35) 1D
$332.00
arrow_downward
-0.29% (-0.97)bedtimeAfter hours
Closed: Nov 9, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PRAX...
Open
$285.00
High
$335.18
Low
$279.14
Mkt. cap
9.30B
Avg. vol.
481.37K
Volume
1.12M
52-wk high
$392.70
52-wk low
$160.11
EPS
-$12.93
Beta
2.85
Shares outstanding
27.92M
No. of employees
168
Open
$285.00
High
$335.18
Low
$279.14
Mkt. cap
9.30B
Avg. vol.
481.37K
Volume
1.12M
52-wk high
$392.70
52-wk low
$160.11
EPS
-$12.93
Beta
2.85
Shares outstanding
27.92M
No. of employees
168
News stories
From web sources and news partners
Yahoo Finance Singapore
·
1 hour ago
Praxis Precision Medicines (PRAX) Stock Looks Rich Against Its Book Value
GuruFocus
·
7 hours ago
PRAX Reiterated by BTIG -- Price Target Maintained at $826
Investing.com Canada
·
9 hours ago
Raymond James reiterates Strong Buy on Praxis Precision Medicines stock By Investing.com
TradingView
·
10 hours ago
PRAX: Ulixacaltamide nears a January decision as launches and pipeline programs advance
About Praxis Precision Medicines Inc
CEO-
Employees168
Founded2015
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitepraxismedicines.com
Analyst ratings
Based on 11 analysts giving stock ratings to PRAX in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for PRAX in the last 3 months.
Highest
Current $332.97
$1,201.00 (+260.69%)
Average
$752.82 (+126.09%)
Lowest
$362.00 (+8.72%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Yasmeen Rahimi Piper Sandler | Buy | Maintained | $1,200.00 | +260.4% | 11/09/2026 |
Kambiz Yazdi BTIG | Buy | Maintained | $826.00 | +148.1% | 11/02/2026 |
Benjamin Burnett Wells Fargo | Hold | Maintained | $362.00 | +8.7% | 10/16/2026 |
Tessa Romero J.P. Morgan | Buy | Initiated | $700.00 | +110.2% | 10/15/2026 |
Douglas Tsao H.C. Wainwright | Buy | Maintained | $1,201.00 | +260.7% | 10/15/2026 |
Joon Lee UBS | Buy | Initiated | $706.00 | +112% | 10/15/2026 |
Justin Walsh JonesTrading | Buy | Reiterated | $534.00 | +60.4% | 10/01/2026 |
Ami Fadia Needham | Buy | Reiterated | $582.00 | +74.8% | 09/24/2026 |
Kevin Strang Goldman Sachs | Buy | Reiterated | $575.00 | +72.7% | 08/21/2026 |
Jay Olson Oppenheimer | Buy | Reiterated | $650.00 | +95.2% | 08/17/2026 |
Tiago Fauth Raymond James | Buy | Maintained | $945.00 | +183.8% | 08/17/2026 |
Danielle Brill Truist Financial | Buy | Maintained | $616.00 | +85% | 08/07/2026 |
Yatin Suneja Guggenheim | Buy | Reiterated | $800.00 | +140.3% | 08/06/2026 |
Brian Skorney Robert W. Baird | Buy | Maintained | $514.00 | +54.4% | 08/07/2026 |
Leonid Timashev RBC Capital | Buy | Reiterated | $462.00 | +38.8% | 08/06/2026 |
Ritu Baral TD Cowen | Buy | Maintained | $510.00 | +53.2% | 08/06/2026 |
Francois Brisebois LifeSci Capital | Buy | Reiterated | $754.00 | +126.4% | 08/08/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $550.00 | +65.2% | 06/30/2026 |
Laura Chico Wedbush | Sell | Maintained | $162.00 | -51.3% | 06/02/2026 |
David Hoang Deutsche Bank | Buy | Maintained | $374.00 | +12.3% | 06/02/2026 |
Unknown Analyst Raymond James | Buy | Initiated | $815.00 | +144.8% | 04/08/2026 |
Rudy Li Wolfe Research | Buy | Maintained | $500.00 | +50.2% | 04/06/2026 |
Last report
Nov 9, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$3.23 / -$3.63
+11.13%beat
arrow_upward
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | 65.80M | 77.51M | 77.99M | 69.42M |
Cost of revenue | 65.80M | 77.51M | 77.99M | 69.42M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 12.56M | 19.54M | 27.87M | 27.49M |
Operating expense | 12.56M | 19.54M | 27.87M | 27.49M |
Total operating expenses | 78.36M | 97.04M | 105.86M | 96.90M |
Operating income | -78.36M | -97.04M | -105.86M | -96.90M |
Other non operating income | - | - | - | - |
EBT including unusual items | -73.93M | -88.91M | -92.56M | -83.72M |
EBT excluding unusual items | -73.93M | -92.50M | -93.22M | -83.72M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -73.93M | -88.91M | -92.56M | -83.72M |
Net profit margin | - | - | - | - |
Earnings per share | -3.36 | -3.50 | -3.20 | -2.87 |
Interest and investment income | 4.42M | 4.54M | 12.64M | 13.18M |
Interest expense | - | - | - | - |
Net interest expenses | 4.42M | 4.54M | 12.64M | 13.18M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -78.34M | -97.02M | -105.82M | -96.87M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events